| From: jmhollen | 3/1/2006 1:16:15 PM | | | | | | GenoMed Awarded Second Patent, for Avoiding Dialysis in Acute Kidney Failure
Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com
ST. LOUIS—March 1, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, announced today that it received its second patent (US Patent #6,998,404) for the "Treatment or prevention of acute renal failure." Acute kidney failure usually happens when a patient gets dehydrated.
Acute kidney failure currently requires a lengthy hospital stay, often involving daily kidney dialysis in the Intensive Care Unit. In addition to the extra cost, acute kidney failure also carries up to a 50% risk of dying. Avoiding dialysis in the first place should greatly improve patient survival and lower healthcare costs.
Said David Moskowitz, MD, FACP, GenoMed's CEO and Chief Medical Officer, "Our patented protocol should be of immediate use to every hospital around the world, especially in places without convenient dialysis. It should be especially useful in disaster zones like New Orleans and earthquakes, as well as the battlefield, where people get dehydrated and go into kidney failure, but can't be dialyzed right away."
Added Dr. Moskowitz, "In a pilot series, our protocol was safe and effective in a dozen newborns and nine adults, including several patients with combined liver and kidney failure, so-called hepato-renal syndrome. We invite interested physicians to collaborate with us in extending these results to additional patients."
About GenoMed
GenoMed finds disease-causing genes, and uses this knowledge to devise new treatment strategies. The Company uses already existing medications whenever possible to maximize safety as well as minimize development costs. GenoMed then passes these savings on to healthcare consumers. GenoMed's treatment for acute kidney failure uses an already existing intravenous medication. An oral form may also work, which would be especially useful in natural disasters and the battlefield.
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 3/8/2006 3:16:13 PM | | | | | | GenoMed Announces Healthchip® to Predict Six Common Cancers Including Lung Cancer
Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com
ST. LOUIS—March 8, 2006--GenoMed (OTC Pink Sheets GMED.PK), a Next Generation Disease Management company whose business is public health™, announced today that it has developed a genomic test for predicting six common cancers: breast, colon, lung, ovarian, pancreatic, and prostate.
GenoMed's test, called the Healthchip®, consists of several hundred single nucleotide polymorphisms (SNPs, pronounced "snips"). Although several more years of tests will be required before FDA approval, the Healthchip® currently identifies patients correctly 85% of the time.
The Healthchip® allows patients to focus their preventive efforts on a single organ. A patient identified as "high risk" for lung cancer, such as Dana Reeve, could get an MRI of her lungs every year or two with the hope that any tumor would be detected at an early enough stage that it could be completely cut out surgically for a cure. Patients at high risk for a particular cancer would need to engage in lifelong surveillance, just as patients at risk for colon cancer undergo repeated colonoscopies their entire life.
Many of the genes that cause cancer will also make excellent targets for new chemotherapy drugs. Because they are more specific to the cancer process, these drugs promise to be less toxic than the currently employed general cellular poisons.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Screening for the six cancers is currently possible in Caucasians only. We would like to extend this work to African American, Asian, and Hispanic patients. We would also like to extend our Healthchip® to include more than the top six solid cancers in adults, as well as cancers in children. Anyone interested is encouraged to contact me at 314.983.9933 or by e-mail, dwmoskowitz@genomed.com ."
About GenoMed
GenoMed finds disease-causing genes, and uses this knowledge to devise new treatment strategies. The Healthchip® is available on a research basis only. Because of genotyping costs, the Healthchip® costs $1,000 for research participants.
.
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 3/9/2006 3:21:13 PM | | | | | | GenoMed's Message for First World Kidney Day: 90% of Kidney Failure in U.S. Can Be Prevented Now
Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com
ST. LOUIS—March 9, 2006--GenoMed (OTC Pink Sheets GMED.PK), a Next Generation Disease Management company whose business is public health, announced today on the eve of the first World Kidney Day that it can prevent up to 90% of chronic kidney disease in the United States.
In September, 2002, GenoMed published a peer-reviewed medical article showing how chronic kidney disease due to diabetes and high blood pressure could be prevented in a total of 1,000 white and black male veterans from St. Louis. In unpublished data, GenoMed's Chief Medical Officer has prevented kidney failure in 350 Hispanic men and women followed since July, 2001 at a free clinic in St. Louis (La Clinica).
Diabetes and high blood pressure account for 90% of kidney dialysis patients in the United States. Medicare currently spends about $25 billion annually on dialysis and kidney transplantation for about 300,000 patients with kidney failure. Since 2000, kidney failure has been increasing at an epidemic rate, 7% per year.
Recovery of kidney function is not possible once a patient is on dialysis. There is a very narrow window of opportunity when prevention is possible: before the patient has lost more than half of their kidney function, that is, when their serum creatinine is still less than 2. (A normal serum creatinine is 1; when it's 10, it's time for dialysis).
Patients are still being seen by their primary care providers below a serum creatinine of 2, and haven't yet seen a kidney doctor. So education of patients and their primary care providers--general internists and family practitioners--is absolutely critical.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "It is fitting that the first World Kidney Day should fall during America's National Patient Safety Week. People of color throughout the world, including the U.S., are even more affected by kidney failure than whites."
Dr. Moskowitz continued, "I am deeply honored to be named today a Defender of Patient Safety by Missouri Watch (http://www.missouriwatch.net). The only thing needed to keep patients off dialysis is just to let them know that it can be done. It's unfortunate that it has taken over three years for the news to get this far. A whole generation of patients who could have been kept off the kidney machine three years ago has gone on to dialysis and an early death."
About GenoMed
GenoMed discovers the genes that cause disease and uses this knowledge to improve patient outcomes. The company's primary commitment is to public health, which involves public education. In addition to having treatments for acute and chronic kidney failure, emphysema, and autoimmune diseases such as psoriasis and alopecia, GenoMed has developed a broad-spectrum anti-viral approach that is expected to work for avian influenza, and has already worked for West Nile virus. GenoMed's anti-viral treatment is specifically mentioned in BioShield II, scheduled for debate this summer in the US Senate (see Section 2151 of Senate bill S. 975). To enroll in GenoMed's free clinical trial for avian influenza or West Nile virus, which uses existing, extremely safe medication already present in every drug store on earth, just go to www.genomed.com and click on the link for either trial.
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 4/12/2006 1:02:22 PM | | | | | | GenoMed Agrees to Distribute Healthcare to India for Under $150 Per Patient Per Year
FOR IMMEDIATE RELEASE
Contact:
David Moskowitz MD
CEO, GenoMed, Inc.
St. Louis, Missouri
www.genomed.com
Tel. 314-983-9933
Email: dwmoskowitz@genomed.com
Ms. Sujata Mital
Director, SUMIT Exports & Trades pvt. Ltd.
Mumbai, India
www.sumitbiomedical.com
Email: sumit_exports@yahoo.com
ST. LOUIS, April 12, 2006 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company whose business is public health™, announced today that it has entered into an exclusive agreement with SUMIT Exports & Trades to market its services to India for under US $150 per patient per year. Since the per capita income in India is around $600 a year, GenoMed has priced its Next Generation DM™ service within reach of the average Indian citizen.
Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, said, "In 2002, we published that we can reverse chronic kidney failure from diabetes and high blood pressure, as well as significantly delay the progression of emphysema. Third World countries like India want to enjoy better health, but can't afford to spend $2 trillion a year on healthcare as the U.S. currently does. Thanks to medical genomics, GenoMed can already deliver better outcomes for cardiovascular disease, which two-thirds of people in First World countries like the U.S. die of. And we have a good jump on cancer, which a third of Americans die of."
Continued Dr. Moskowitz, "Yesterday, at the BIO 2006 convention in Chicago, former President Clinton called biotechnology the answer to international healthcare. Today, we're delighted to prove him right. We look forward to the expansion of President Bush's Health Savings Accounts (HSA's) to make preventive molecular medicine and lower health care costs a reality in the United States one day, too."
About GenoMed™
GenoMed is the only biotechnology company serious about both lowering healthcare costs and improving patient outcomes. It is leading the clinical revolution made possible by knowing which genes cause which diseases. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company is offering its Healthchip®, on a research basis only, to predict breast, colon, lung, ovarian, pancreatic, and prostate cancer in Caucasians. And GenoMed is in the process of creating a virtual pharmaceutical company to develop new drugs for the hundreds of cancer chemotherapy targets it has discovered, in situations where no drug yet exists.
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 4/19/2006 9:52:11 AM | | | | | | GenoMed to Offer Free Mumps Trial
Contact: David Moskowitz MD
CEO, GenoMed, Inc.
Tel. 314-983-9938
Email: dwmoskowitz@genomed.com
ST. LOUIS—April 19, 2006--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED.PK) a St. Louis, Missouri-based Next Generation Disease Management company whose business is public health™, announced today that it is offering a free clinical trial for mumps, using already existing medications. (The cost of the drugs, about $1 a day, is extra).
GenoMed believes a class of safe, already existing blood pressure pills may be a near-universal viral antidote, making vaccines and antiviral drugs unnecessary for most viruses except for the tiny fraction of the population which is immunosuppressed. GenoMed's approach has been successful for treating West Nile virus encephalitis in humans for the past 3 summers, and in birds for the past 2 summers. The first 8 patients were published in a peer-reviewed medical journal in 2004.
Said David Moskowitz, MD, GenoMed's CEO and Chief Medical Officer, "Unlike West Nile virus, the mumps virus is no more lethal than the common cold, but it causes a lot of discomfort. As with most viruses, disease in humans is caused by a 'cytokine storm,' not by the virus itself. Our approach is to calm the 'cytokine storm' in the host and ignore the virus. Our goal is to turn the patient into an asymptomatic shedder, which is what happens normally."
Added Dr. Moskowitz, "Our approach should work for most viruses in most people and animals. The more experience we get with different viruses, the more credible this approach becomes, and the readier we'll be for something really big, like avian flu or a viral bioterrorist attack."
GenoMed holds a pending patent for its approach in the U.S. but not the rest of the world. It was included in the Project BioShield Act of 2005 co-sponsored by Senators Lieberman, Hatch, and Brownback (see Section 2151 of Senate bill S.975, available at: govtrack.us. Introduced a year ago, this bill has not yet been discussed. The White House requested a briefing about GenoMed's possible viral antidote in the summer of 2004, and the Department of Homeland Security and the National Institutes of Health agreed to a briefing in the fall of that year. For the past three years, the World Health Organization has not returned any phone calls or emails on this subject. The Centers for Disease Control complained to the FDA about GenoMed's West Nile virus trial in June, 2004, but the FDA dropped the case as soon as it began investigating it in August, 2005.
To enroll in GenoMed's free clinical trial for mumps, simply contact Dr. Moskowitz.
About GenoMed
GenoMed is a Next Generation DM(tm) company that has found what it believes to be the "master" disease gene. It has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of end-stage emphysema; and begin to see success in treating cancer and autoimmune diseases. GenoMed's near-universal viral antidote is simply another consequence of the "master" disease gene, which alone promises to revolutionize healthcare globally. Despite the usual obstacles facing any biotech start-up company, GenoMed perseveres in its mission to improve public health through genomics, promising a significant return to both patients and shareholders.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Tadsamillionaire | 5/12/2006 9:05:12 PM | | | | | | MO Rep. Mott Oxford Congratulates GenoMed on Reversing Kidney Failure
ST. LOUIS, May 2 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health(TM), announced today that Missouri State Representative Jeanette Mott Oxford has offered her congratulations to GenoMed on its novel treatment for chronic kidney failure.
GenoMed was the first to prove that chronic kidney failure may not be so chronic after all, at least early in its course. GenoMed's CEO, David Moskowitz MD, showed that chronic kidney failure due to diabetes or high blood pressure can actually be reversed early in the course of the disease.
Said the Honorable Ms. Mott Oxford, Representative for Missouri's 59th House District, 'Prevention of dialysis will save federal dollars and allow a much better quality of life for Missourians. The State of Missouri will benefit from healthier, more productive people who can continue to help others, rather than be a burden themselves.'
Rep. Mott Oxford continued, 'I am particularly excited by the implication this has for our state Medicaid budget. If kidney disease from diabetes and high blood pressure can be controlled, then maybe heart disease and other complications can be, too. If so, the cost of cardiovascular disease could finally be reduced in Missouri.'
Rep. Mott Oxford added, 'Dr. Moskowitz came to my attention a few years ago when he fought for a friend of mine with emphysema to receive proper treatment in a system that wanted to deny him needed medicines. As time has passed, my admiration has only grown.'
Dr. Moskowitz was recently presented with the 2006 Defender of Patient Safety Award (physician category) by Missouri Watch ( missouriwatch.net ). His results were published in Diabetes Technology and Therapeutics, a peer-reviewed medical journal, in September, 2002. If applied nationally, Dr. Moskowitz's method could prevent up to 90% of dialysis, and save Medicare over $22 billion a year. GenoMed owns the patents pending for this novel treatment approach |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: donpat who wrote (298) | 6/22/2006 9:55:53 AM | | From: jmhollen | | | | They seem to have the goods, but they're bucking the snooty AMA establishment.
If they had/received the funding to do proper marketing and break out, it could be a good one.
John :-)
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: donpat who wrote (298) | 6/28/2006 7:45:37 PM | | From: Tadsamillionaire | | | | GenoMed CEO Invited to Lecture at University of Chicago About Bird Flu
ST. LOUIS, June 21 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is global public health(TM), today announced that its CEO was invited to speak at the Department of Medicine of the University of Chicago about diseases associated with the angiotensin I-converting enzyme (ACE), including avian influenza ('bird flu').
Dr. Skip Garcia, Chairman of the Medicine Department, invited GenoMed's CEO, David Moskowitz, MD, for a two day Visiting Lectureship that ended yesterday. Dr. Garcia is a world-famous lung specialist whose research group is looking for drugs to decrease the 'cytokine storm' created by the avian influenza virus.
GenoMed has filed patent applications claiming that ACE inhibitors and angiotensin II blockers can do exactly that. Furthermore, these drugs may be a near-universal viral antidote, because people who get sick from all viral diseases suffer from a 'cytokine storm.' GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal response to viral bioterrorism.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. We're extremely gratified that a world-class research institution like the University of Chicago is thinking along exactly the same lines. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Tadsamillionaire who wrote (300) | 6/28/2006 7:46:26 PM | | From: Tadsamillionaire | | | | GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension
ST. LOUIS, June 26 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is global public health(TM), today announced that it has already published why patients with diabetes and high blood pressure should be at increased risk of getting West Nile virus encephalitis.
This observation has now been made in California, New York and Texas.
The link appears to be over-activity of the angiotensin I-converting enzyme, abbreviated 'ACE.'
In 2002, GenoMed published a series of four papers showing that over- activity of ACE led to diabetes and hypertension, as well as to complications like heart and kidney disease. Using the right dose of the right ACE inhibitor, it was possible to reverse diabetic or hypertensive kidney disease for the first time.
In 2004, GenoMed published that a similar approach was successful in treating over 80% of patients with West Nile virus encephalitis. GenoMed's treatment success rate for WNV encephalitis is currently 86% (19 of 22 patients improved rapidly).
In 2003, GenoMed filed patent applications claiming that ACE inhibitors and angiotensin II blockers may be a near-universal viral antidote, because previously healthy people who get sick from nearly all viral diseases suffer from a 'cytokine storm' initiated by too much angiotensin II. Angiotensin II is made by ACE. GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal public health response to viral bioterrorism.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. It's very gratifying to get separate epidemiologic confirmation that we've discovered something huge.' |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
